Withus Pharmaceutical Co

Withus Pharmaceutical Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Withus Pharmaceutical Co (330350.KQ) as of Nov 5, 2026 is 5.66 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 7.03 B KRW — a change of -19.40% (lower).

EBITDA

5.66 BKRW

YoY

-19.40%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Withus Pharmaceutical Co is 2025 5.66 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Withus Pharmaceutical Co was 2024 7.03 B KRW. It decreases by -19.40% lower compared to the previous year.

The Withus Pharmaceutical Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
11.04 B KRW
Jan 1, 2019
10.07 B KRW
Jan 1, 2020
1.56 B KRW
Jan 1, 2021
5.48 B KRW
Jan 1, 2022
5.85 B KRW
Jan 1, 2023
9.24 B KRW
Jan 1, 2024
7.03 B KRW
Jan 1, 2025
5.66 B KRW
The Withus Pharmaceutical Co EBITDA history
YEAREBITDAYoY
5.66 BKRW-19.40%
7.03 BKRW-23.94%
9.24 BKRW+57.87%
5.85 BKRW+6.76%
5.48 BKRW+251.45%
1.56 BKRW-84.51%
10.07 BKRW-8.80%
11.04 BKRW-3.01%
11.38 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Withus Pharmaceutical Co Stock analysis

What does Withus Pharmaceutical Co do? Withus Pharmaceutical Co Ltd is a pharmaceutical company based in Seoul, South Korea, operating within the healthcare sector. The company focuses on the manufacturing and distribution of prescription drugs, with its headquarters located in Seoul. As of the latest available information, Withus Pharmaceutical employs 191 full-time staff members. The company completed its initial public offering (IPO) on July 3, 2020, marking its entry into the public market. Its primary product categories include circulatory agents, musculoskeletal agents, digestive agents, antibiotics, and other prescription medications. Additionally, the company engages in contract manufacturing operations (CMO), providing manufacturing services for other pharmaceutical entities. Withus Pharmaceutical maintains a corporate website at https://www.withuspharm.com/mastart/mastart.php, which serves as a platform for company information and updates. The company operates in the pharmaceutical industry, contributing to the production and supply of essential medications in South Korea. Withus Pharmaceutical's business model integrates both direct product sales and contract manufacturing services, supporting its role in the broader healthcare ecosystem. The company's operations are centered around the development and delivery of prescription drugs, with a focus on key therapeutic areas such as cardiovascular health, musculoskeletal conditions, gastrointestinal treatments, and infectious disease management. The firm's activities are conducted under the regulatory framework of South Korea's pharmaceutical industry, adhering to local standards for drug manufacturing and distribution. Withus Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Withus Pharmaceutical Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Withus Pharmaceutical Co is 5.66 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Withus Pharmaceutical Co changed from 7.03 B KRW to 5.66 B KRW, representing a -19.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Withus Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Withus Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Withus Pharmaceutical Co

All Key Metrics — Withus Pharmaceutical Co